{"schema_version":"1.0","type":"article","title":"Depression Trial Success Faces a Replication Test","url":"https://drugnews.com.tw/articles/2026-11-21-helus-hlp003-depression-phase3-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-21-helus-hlp003-depression-phase3-en.md","lang":"en","date":"2026-11-21","publish_at":"2026-11-21T08:00:00+08:00","updated_at":"2026-11-21","category":"商業分析系列","topic":"臨床與 CMC","tags":["憂鬱症","精神醫學","臨床試驗","Helus"],"summary":"HLP003 cleared a controlled depression trial. Replication and workable treatment delivery now determine its product case.","key_points":["HLP003 has earned further development, while replication and deliverable care determine its product case.","APPROACH reported placebo-adjusted benefit; population and background treatment constrain comparisons.","Taiwan access requires local authorization and a feasible care pathway."],"facts":[{"claim":"事件最早公開日","value":"2026-11-16","unit":"date","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"APPROACH研究階段","value":3,"unit":"phase","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第6週主要評估時點","value":6,"unit":"week","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第6週安慰劑校正MADRS差","value":-7.6,"unit":"point","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第12週關鍵次要評估時點","value":12,"unit":"week","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第12週安慰劑校正MADRS差","value":-7,"unit":"point","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第6週HLP003緩解率","value":50.9,"unit":"percent","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"第6週安慰劑緩解率","value":18.2,"unit":"percent","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"緩解門檻MADRS","value":10,"unit":"point_upper_bound","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"同研究緩解率絕對差","value":32.7,"unit":"percentage_point","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"NNT未取整","value":3.058103975535168,"unit":"person","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"NNT向上取整","value":4,"unit":"person","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"治療相關嚴重不良事件","value":3,"unit":"event","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"EMBRACE公司預期讀出","value":"2027-Q4","unit":"forecast","as_of":"2026-11-17","source":"https://ir.helus.com/node/11511/pdf"},{"claim":"SPRAVATO給藥後觀察下限","value":2,"unit":"hour","as_of":"2026-11-17","source":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf"}],"sections":["01｜Subtract placebo to see the added effect","02｜Three companies at different stages of evidence","03｜Remission looks promising; replication and safety come next","04｜Taiwan: from monitoring documents to local treatment","References"],"references":[{"title":"APPROACH positive topline results","source":"Helus Pharma","date":"2026-11-16","url":"https://ir.helus.com/node/11511/pdf"},{"title":"APPROACH record NCT06564818","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT06564818"},{"title":"EMBRACE record NCT06793397","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT06793397"},{"title":"EXTEND record NCT06605105","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT06605105"},{"title":"SPRAVATO prescribing information","source":"FDA","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf"},{"title":"SPRAVATO monotherapy announcement","source":"Johnson & Johnson","date":"2025-01-21","url":"https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression"},{"title":"COMP360 second Phase 3 follow-up","source":"Compass Pathways","date":"2026-07-07","url":"https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/default.aspx"},{"title":"Psychedelic Drugs: Considerations for Clinical Investigations","source":"FDA","date":"","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations"},{"title":"SPRAVATO Taiwan prescribing document","source":"Kaohsiung Municipal Kai-Syuan Psychiatric Hospital","date":"","url":"https://ksph.kcg.gov.tw/7/dfiles_pdf/Spravato.pdf"},{"title":"Medication safety","source":"Taiwan Ministry of Health and Welfare","date":"","url":"https://www.mohw.gov.tw/cp-88-216-1.html"},{"title":"National Health Insurance pharmaceutical inclusion and payment rules","source":"Taiwan Laws and Regulations Database","date":"","url":"https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0060035"}],"images":[{"alt":"Figure 1｜The placebo-adjusted effect","url":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3-en/figure-01.png"},{"alt":"Figure 2｜The serotonin mechanism hypothesis","url":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3-en/figure-02.png"},{"alt":"Figure 3｜Calculating absolute benefit from remission rates","url":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3-en/figure-03.png"},{"alt":"Figure 4｜A treatment-delivery pathway in Taiwan","url":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/helus-hlp003-depression-phase3-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-21）。Depression Trial Success Faces a Replication Test。https://drugnews.com.tw/articles/2026-11-21-helus-hlp003-depression-phase3-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “HLP003 has earned further development, while replication and deliverable care determine its product case”?","a":"HLP003 has earned further development, while replication and deliverable care determine its product case."},{"q":"What are the key developments in “APPROACH reported placebo-adjusted benefit”?","a":"APPROACH reported placebo-adjusted benefit; population and background treatment constrain comparisons."},{"q":"What are the key developments in “Taiwan access requires local authorization and a feasible care pathway”?","a":"Taiwan access requires local authorization and a feasible care pathway."}]}